WaveMan
WaveMan · Company
BMEA · Biomea Fusion, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BMEA Biomea Fusion (BMEA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001840439
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
32
13F, latest reported quarter

Biomea Fusion insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Biomea Fusion, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Erdtmann Rainer M
See Remarks
BUY
2025-12-15 SECtraded 2025-12-11
30,000
$42.9K
-53.1%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Dec 1, 2025.
  • +8.5% median (+8.0% mean) 90-day return after 6 previous buys.
  • The trade is 4.1% of the 723,027 shares held after it.
  • 1 other insider bought within 30 days.
  • 32 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Erdtmann Rainer M bought about $42.9K of BMEA on Dec 11, 2025; 1 other insider bought within 30 days and 32 funds added in the latest 13F quarter.
Hitchcock Michael J.M.
Interim CEO
BUY
2025-12-04 SECtraded 2025-12-02
100,000
$99.0K
-47.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Sep 30, 2024.
  • -14.9% median (-14.9% mean) 90-day return after 2 previous buys.
  • The trade is 87.0% of the 115,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 32 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Interim CEO Hitchcock Michael J.M. bought about $99.0K of BMEA on Dec 2, 2025, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 32 funds added in the latest 13F quarter.
Erdtmann Rainer M
See Remarks
BUY
2025-12-02 SECtraded 2025-12-01
10,000
$10.5K
-38.8%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Nov 28, 2025.
  • +7.4% median (+2.4% mean) 90-day return after 5 previous buys.
  • The trade is 1.4% of the 693,027 shares held after it.
  • 1 other insider bought within 30 days.
  • 32 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Erdtmann Rainer M bought about $10.5K of BMEA on Dec 1, 2025; 1 other insider bought within 30 days and 32 funds added in the latest 13F quarter.
Erdtmann Rainer M
See Remarks
BUY
2025-12-02 SECtraded 2025-11-28
40,000
$44.0K
-38.8%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Aug 23, 2021.
  • -2.7% median (-5.2% mean) 90-day return after 4 previous buys.
  • The trade is 5.9% of the 683,027 shares held after it.
  • 1 other insider bought within 30 days.
  • 32 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Erdtmann Rainer M bought about $44.0K of BMEA on Nov 28, 2025, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 32 funds added in the latest 13F quarter.
Hitchcock Michael J.M.
Director
BUY
2024-10-01 SECtraded 2024-09-30
10,000
$100.6K
-93.7%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 14, 2022.
  • The trade is 66.7% of the 15,000 shares held after it.
  • No other insider bought within 30 days.
  • 32 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hitchcock Michael J.M. bought about $100.6K of BMEA on Sep 30, 2024, the largest insider purchase at the company since 2023; 32 funds added in the latest 13F quarter.
33 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 28 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
32 funds bought in last quarter
below 61% of Pharma & Biotech
Revenue
+0.0% year over year (latest quarter)
below 56% of Pharma & Biotech
Margin
-0.8% net margin (latest quarter)
more than 73% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
23.2% of the float short (float per yahoo 2026-10-27) · 4.8 days to cover · settled 2026-10-15
more than 96% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BMEA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-53.4%12M
-58%-18%+21%+60%2025-102025-122026-022026-042026-062026-082026-10 2025-12-02 · Hitchcock Michael J.M. bought $99.0K2025-11-28 · Erdtmann Rainer M bought $44.0K2025-12-11 · Erdtmann Rainer M bought $42.9K2025-12-01 · Erdtmann Rainer M bought $10.5K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BMEA: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
8,814,946 sh
$13.0M
VANGUARD CAPITAL MANAGEMENT LLC
2,829,927 sh
$4.2M
MARSHALL WACE, LLP
2,049,802 sh
$3.0M
Aisling Capital Management LP
2,048,757 sh
$3.0M
RENAISSANCE TECHNOLOGIES LLC
1,455,474 sh
$2.1M

Congress trades in BMEA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BMEA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

BMEA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$124.4K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$339.6K position · as of 2026-06-30
0.0%
Select Biotechnology Portfolio
$624.7K position · as of 2026-05-31
0.0%
1290 VT Micro Cap Portfolio
$22.9K position · as of 2026-06-30
0.0%
Fidelity Growth Company K6 Fund
$1.3M position · as of 2026-05-31
0.0%
Fidelity Series Growth Company Fund
$1.1M position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
9 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
5
Phase 1
0 active
3
Phase 2
2 active
1
Multi-phase
0 active
What changed recently
Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants
2026-10-28 · Completion moved 2026-05 → 2026-08-12
Phase 1
Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants
2026-10-28 · Active Not Recruiting → Completed
Phase 1
A Phase 1 Study of BMF-500 in Adults With Acute Leukemia
2026-09-24 · Active Not Recruiting → Completed
Phase 1
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 32 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

BMEA financials

Revenue growth
0.0%
XBRL, annual
Net margin
-0.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$47.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-164.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-59.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-141.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-101.5%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$83.5M-$144.1M-$126.1M-$83.6M
Net income-$61.8M-$138.4M-$117.3M-$81.8M
EPS (diluted)-1.18-3.83-3.44-2.80
Operating cash flow-$70.4M-$119.9M-$96.6M-$62.4M
Cash$55.8M$58.3M$176.9M$111.9M
SEC XBRL, fiscal years, as known on 2026-10-28

BMEA Stock Sonar score 4/7 axes

Find similar shapesCompare

BMEA ranks highest on growth (44th percentile) and risk and compliance (40th), and lowest on profitability (26th), among Pharma & Biotech peers.

Profitability
26
Inputs
  • Return on equity-164.1% · 21 pct, sector of 545
  • Return on assets-59.1% · 38 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-141.6% · 17 pct, sector of 576
Growth
44
Inputs
  • Revenue growth, YoY+0.0% · 44 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
39
Inputs
  • Funds adding, latest quarter32 · 39 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
40
Inputs
  • Short interest, % of float+23.2% · 9 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+6.9% · 72 pct, sector of 511
3 not measured: Financial health, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies